TOKYO, Mar 09 (Pulse News Wire) – PATH Corporation (3840.T) announced today that its subsidiary RMDC has entered into a strategic partnership with Korean biotechnology firm MediPost Co., Ltd. The agreement includes joint development of next-generation automated cell manufacturing robots and implementation of physical AI technology.
Under the partnership, RMDC's advanced automation systems will be integrated into MediPost’s production lines to enhance efficiency and quality control. Additionally, both companies will collaborate on developing AI algorithms capable of replicating skilled technicians' expertise, aiming to optimize robotic operations for precise cell cultivation processes. MediPost will serve as the exclusive distributor of RMDC's next-gen robots in South Korea, accelerating market penetration and sales growth. The capital of MediPost stands at 17,108,892,500 KRW, with major shareholders including SkyMedi Co., Ltd.
Holding 21.42% and Marble 2022 Holdings Co., Ltd. holding 20.11%. In recent years, the global challenge of scaling up cell manufacturing while maintaining high-quality standards has intensified. This collaboration seeks to address these issues through advanced automation and AI integration, positioning RMDC as a leader in the field.
🟢 Confidence: High AI-translated content.